
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings is a promising gene therapy company with a vertically integrated pipeline that includes targeted therapies for serious diseases such as Parkinson's and rare inherited retinal dystrophies. The recent partnership deal with Hologen for their Parkinson's program brings in much needed financing and support, and the company's strong manufacturing capabilities set them up for success in developing and commercializing their therapies. With multiple potential launches in the pipeline and a solid balance sheet, this company has the potential to become a commercial-stage success in the near future.
Bears say
MeiraGTx Holdings is a company with a promising pipeline but faces significant risks and uncertainties in terms of clinical program execution and regulatory approvals. Its success will depend on its ability to effectively demonstrate the efficacy of its treatments and maintain a competitive edge in the market. However, the company's focus on sustainable and disease-modifying options in areas with high unmet need could provide growth potential and increased value in the long term, if successful.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares